Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Kymera Therapeutics (KYMR) over the last 5 years, with Dec 2024 value amounting to -$2.98.

  • Kymera Therapeutics' EPS (Weighted Average and Diluted) fell 14.63% to -$0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.60, marking a year-over-year decrease of 53.85%. This contributed to the annual value of -$2.98 for FY2024, which is 18.25% down from last year.
  • As of FY2024, Kymera Therapeutics' EPS (Weighted Average and Diluted) stood at -$2.98, which was down 18.25% from -$2.52 recorded in FY2023.
  • Kymera Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$2.09 for FY2021, and its period low was -$3.15 during FY2020.
  • Over the past 3 years, Kymera Therapeutics' median EPS (Weighted Average and Diluted) value was -$2.87 (recorded in 2022), while the average stood at -$2.79.
  • In the last 5 years, Kymera Therapeutics' EPS (Weighted Average and Diluted) surged by 33.65% in 2021 and then crashed by 37.32% in 2022.
  • Kymera Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$3.15 in 2020, then spiked by 33.65% to -$2.09 in 2021, then slumped by 37.32% to -$2.87 in 2022, then rose by 12.20% to -$2.52 in 2023, then dropped by 18.25% to -$2.98 in 2024.